When can preventive therapy be safely discontinued in patients with tension‑type headache or chronic migraine?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

When to Safely Discontinue Preventive Therapy for Tension-Type Headaches and Chronic Migraine

For episodic migraine, consider tapering preventive medications after 3-6 months of sustained improvement; for chronic migraine, wait 6-12 months before attempting discontinuation, with close monitoring for clinical deterioration. 1

Timing of Discontinuation

Episodic Migraine

  • Taper after 3-6 months of sustained clinical improvement 1
  • The 2025 ACP guideline acknowledges uncertainty about when to discontinue but emphasizes reevaluating the balance of benefits, harms, and costs with the patient 2

Chronic Migraine

  • Wait 6-12 months before attempting discontinuation 1
  • This longer duration reflects the more severe disease burden and higher risk of relapse

Critical Considerations by Medication Class

CGRP(-Receptor) Antibodies

Exercise significant caution with discontinuation - the evidence strongly suggests rapid deterioration:

  • Expect clinical worsening within 1-3 months after stopping 3, 4, 5
  • Monthly migraine days increase by approximately 4.4 days at 3 months post-discontinuation 4
  • Headache impact (HIT-6 scores) worsens significantly, with changes exceeding minimally clinically important differences 3
  • The ≥50% responder rate drops dramatically (RR 0.42) after cessation 4

Important caveat: Despite worsening after discontinuation, patients typically maintain some improvement compared to pre-treatment baseline (mean reduction of -3.78 monthly migraine days persists) 4. However, the rapid deterioration after stopping suggests these medications may need to be continued longer than traditional oral preventives, and current 6-12 month discontinuation recommendations may be premature 5.

OnabotulinumtoxinA

  • "Super-responders" may maintain benefit for at least 6 months after discontinuation 6
  • Patients with chronic daily headache < 6 months duration at baseline are more likely to sustain improvement 6
  • Those requiring fewer treatment cycles to achieve response have better outcomes after stopping 6
  • Consider longer treatment duration before attempting discontinuation compared to oral preventives

Oral Preventives (Topiramate, Amitriptyline, Candesartan)

  • Follow the 3-6 month rule for episodic migraine, 6-12 months for chronic migraine 1
  • Limited real-world data on discontinuation outcomes for these agents

Monitoring Strategy During Discontinuation

Use a headache diary to objectively track:

  • Monthly migraine/headache days
  • Acute medication consumption
  • Headache impact on daily function 2

Assess at 4-week intervals initially after stopping treatment, as deterioration can occur rapidly (within the first month for CGRP antibodies) 3

When NOT to Discontinue

Avoid discontinuation attempts in patients with:

  • Baseline chronic daily headache > 6 months duration (higher relapse risk) 6
  • Medication overuse at baseline or current
  • Profound disability from migraine
  • History of multiple preventive failures before current successful treatment
  • Complicated migraine with debilitating auras or history of migrainous infarction 1

Common Pitfalls

  1. Premature discontinuation of CGRP antibodies: German guidelines recommend 6-12 months, but emerging evidence suggests this may be too early given the rapid and clinically meaningful deterioration observed 3, 5

  2. Failing to monitor systematically: Without objective tracking via headache diary, subtle deterioration may be missed until significant worsening occurs 2

  3. Not preparing patients for potential relapse: Patients should understand that retreatment is often necessary and effective if deterioration occurs 5

Retreatment Considerations

If clinical worsening occurs after discontinuation:

  • Retreatment is typically effective, restoring previous benefit levels 5
  • For CGRP antibodies, improvement after retreatment occurs within 1-2 months 5
  • Consider this a "failed discontinuation attempt" rather than treatment failure

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.